Abstract: The invention relates to a method for prognosing disease progression in a patient that has or is at risk of developing a severe acute respiratory syndrome (SARS), wherein the method comprises determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in a sample from the patient, wherein said level indicates the severity of SARS progression. The method is in some embodiments configured for use when a patient exhibits symptoms of a severe acute respiratory syndrome (SARS), a patient exhibits symptoms of infection with a SARS-virus, the patient is infected with a SARS-virus, such as a SARS-coronavirus, such as SARS-CoV2.

Abstract: Improved methods and systems for active surveillance are generally described. For example, methods comprising subjecting the blood sample of the subject to one or more immunoassays that measure levels of kallikrein markers comprising free prostate specific antigen (fPSA), intact prostate specific antigen (iPSA), total prostate specific antigen (tPSA) and human kallikrein 2 (hK2); and determining the probability that a prostate tissue biopsy obtained from the subject would contain detectable aggressive prostate cancer using a logistic regression model with aggressive prostate cancer as the outcome are described.

Abstract: A method of assessing the risk for development of cardiovascular disease (CVD) or an inflammatory disease in a patient comprises (i) incubating a sample of body fluid with donor particles, wherein the donor particles are coated with a lipid and a first quantity of detectably labeled, non-exchangeable lipid probe (NELP); (ii) separating the detectably labeled NELP-associated HDL into a first portion and the donor particles into a second portion; (iii) measuring the second quantity of detectably labeled NELP in the first portion; (iv) determining a detectably labeled NELP efflux value for the patient; and (v) comparing the detectably labeled NELP efflux value for the patient to a reference standard. Related methods of lowering the risk for development of CVD or an inflammatory disease in a patient and methods of measuring the quantity of functional HDL in a sample of body fluid are also provided.

Abstract: The present disclosure is directed to a method for separating a biomolecule from a cell culture or from a biological solution, comprising the steps of: (a) providing magnetic particles comprising ligands capable of binding the biomolecule; (b) contacting a cell culture or a biological solution comprising the biomolecule with the magnetic particles to obtain magnetic particles comprising the bound biomolecule; (c) retaining the magnetic particles with a magnetic field in a magnetic separator; (d) optionally washing the magnetic particles with a washing liquid; (e1) providing a flow of an elution liquid through the magnetic separator to elute the bound biomolecule from the magnetic particles while retaining the magnetic particles with the magnetic field in the magnetic separator; (f1) forwarding the biomolecule eluted from the magnetic separator to a membrane chromatography device; (g1) separating the biomolecule from impurities and/or contaminants by membrane chromatography.

Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract: The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.

Abstract: The current disclosure provides antibodies that bind to peptides associated with the primary immunodeficiency disorders (PIDD) Wiskott-Aldrich Syndrome (WAS) and X-linked agammaglobulinemia (XLA). The antibodies can be used in peptide immunoaffinity enrichment coupled to selected reaction monitoring mass spectrometry (immuno-SRM) assays for clinical diagnosis and newborn screening of WAS and XLA, among other uses.

Abstract: The present invention provides a porous hollow fiber membrane and methods of using the membrane to select an immune checkpoint inhibitor. The membrane can be used in animal models with an immune system and using a low-cost common mouse. The host immune system is unable to attack the cancer cells within the membrane and an animal study proves that the membrane system can be performed within animals.

Abstract: The present disclosure provides a method for automatic sampling of immune cells from a biological fluid sample, e.g., whole blood, deposited in a well of a microwell plate. The microwell plate is placed on a shaker having a magnetic adapter including at least one magnet. The magnet causes red blood cells (RBCs) bound to magnetic beads to be attracted to and migrate to a wall of the well. The shaker is then operated to shake the microwell plate such that the immune cells are substantially isolated from the RBCs in a region of the well. A sample probe is then lowered into the region of the well to withdraw a portion of the sample containing the immune cells.

Abstract: Provided are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.